Tuesday, October 16, 2007

Accentia Biopharmaceuticals to Rise on Significant Developments - Seeking Alpha
Revimmune is the first drug to propose restoration of lost function in MS patients. Using a patent-pending, ultra-high intensity, short-course of an intravenous formulation of cyclophosphamide
http://seekingalpha.com/article/49405-accentia-biopharmaceuticals-to-rise-on-significant-developments

http://tinyurl.com/3ba76c

Accentia Biopharmaceuticals to Rise on Significant Developments
Seeking Alpha - New York,NY,USA
Which is Accentia's potential theraputic for refractory, relapsing remitting Multiple Sclerosis. The Revimmune MS study will enroll subjects in a one-year ...
See all stories on this topic

Gene Therapy Drug Shows Promise in MS Patients
ClinicalTrialsToday - Boston,MA,USA
By Tracy Trundle Palo Alto, Calif-based Bayhill Therapeutics released positive results from a phase IIb trial of BHT-3009 for the treatment of multiple ...
See all stories on this topic

NRP drug effective in animal models of motor neuron disease and ...
PipelineReview.com (press release) - Barcelona,Spain
New treatments are needed for MND as the only available prescription is riluzole, a drug that extends life expectancy by only three months. ...
See all stories on this topic

Analyst initiations: STD, SLH, FCN and BCSI
BloggingStocks - USA
Societe Generale expects the Banco Santander's (NYSE: STD) strong organic growth in earnings to continue with the purchase of ABN Amro's (NYSE: ABN) assets ...
See all stories on this topic

Cigarettes Worsen Symptoms of MS
MedHeadlines - Chicago,IL,USA
... from relapsing-remitting MS and experienced severe attacks with complete or partial recovery, 9 participants suffered from primary-progressive MS, ...
See all stories on this topic

Simple Eye Scan Opens Window To Multiple Sclerosis
Science Daily (press release) - USA
Twenty had relapsing remitting MS, 15 had secondary progressive MS, and five had primary progressive MS. Researchers also recruited 15 healthy control ...
See all stories on this topic

Genzyme Shares Rise on Campath Study
CNNMoney.com - USA
NEW YORK (Associated Press) - Shares of biotechnology company Genzyme Corp. jumped to a new high Monday after the company said its leukemia drug Campath was ...
See all stories on this topic

German Stocks Including TUI, Siemens Decline; RWE Shares Rise
Bloomberg - USA
Germany's largest drugmaker said its Campath multiple sclerosis treatment was more effective than Merck KGaA's Rebif. The risk of an illness outbreak after ...
See all stories on this topic

Sector Glance: Biotechnology Mixed
Houston Chronicle - United States
Genzyme Corp. shares rose after it reported positive midstage study results for its Campath as a prospective multiple sclerosis drug. ...
See all stories on this topic

On The Move For Monday, Oct. 15
Forbes - NY,USA
Shares of biotech company Genzyme rose more than 5% on news that its leukemia drug Campath proved more effective than Merck's candidate in treating multiple ...
See all stories on this topic

HEART TO HEART TALK Drug improves stroke outcomes
Inquirer.net - Philippines
The drugs is minocycline, a semi-synthetic, second-generation derivative of the antibiotic tetracycline that has already been found to have significant ...
See all stories on this topic

A five-minute eye exam might help gauge multiple sclerosis
ANI via Yahoo! India News Tue, 16 Oct 2007 1:18 AM PDT
Washington, Oct 16 (ANI): A Johns Hopkins study has revealed that a five-minute eye exam might prove to be an inexpensive and effective way to gauge and track the debilitating neurological disease multiple sclerosis. The new method can potentially complement costly magnetic resonance imaging (MRI) to detect brain shrinkage - a characteristic of the disease's progression The new study is ...

Potential New Diagnositc For Multiple Sclerosis From Simple Eye Scan
Medical News Today Tue, 16 Oct 2007 5:15 AM PDT
A five-minute eye exam might prove to be an inexpensive and effective way to gauge and track the debilitating neurological disease multiple sclerosis, potentially complementing costly magnetic resonance imaging to detect brain shrinkage -- a characteristic of the disease's progression. [click link for full article]

Top-Line Efficacy Data Presented From Phase 2 Trial Of Alemtuzumab In Multiple Sclerosis
Medical News Today Tue, 16 Oct 2007 1:16 AM PDT
Genzyme Corporation (Nasdaq: GENZ) announced that top-line, three-year data from a completed Phase 2 clinical trial comparing alemtuzumab with Rebif(R) (interferon beta- 1a) for the treatment of multiple sclerosis were presented this weekend at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague. [click link for full article]

Transformation of Treatment Paradigm to Improve Patient Compliance with Multiple Sclerosis Therapy
Business Wire via Yahoo! Finance Tue, 16 Oct 2007 5:30 AM PDT
PALO ALTO, Calif.----The multiple sclerosis market is undergoing a revolution with the imminent introduction of innovative therapies that will change the approach toward the treatment of the disease.

Eye Scan May Help Spot MS Damage
WebMD Tue, 16 Oct 2007 9:15 AM PDT
An eye scan that measures nerve thickness in the retina may help gauge nerve damage from multiple sclerosis, experts note in Neurology.

Big vote on health
Boston Globe Tue, 16 Oct 2007 2:19 AM PDT
Liz Casey functions a lot better than many people who suffer, as she does, from multiple sclerosis.

Study Suggests FTY720 May Repair MS Damage By Direct Effect On Brain
Medical News Today Tue, 16 Oct 2007 11:16 AM PDT
FTY720 (fingolimod), an oral sphingosine-1-phosphate receptor agonist being developed for multiple sclerosis (MS), acts directly on the central nervous system (CNS) to reduce disease severity in addition to peripheral effects on the immune system, according to results from a model of the disease repo [click link for full article]

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home